Efficacy of fluticasone propionate on lung function and symptoms in wheezy infants.

Division of Respiratory Medicine, Department of Pediatrics, Erasmus University MC/Sophia Children's Hospital, P.O. Box 2060, 3000 CB Rotterdam, The Netherlands.
American Journal of Respiratory and Critical Care Medicine (Impact Factor: 11.99). 03/2005; 171(4):328-33. DOI: 10.1164/rccm.200402-227OC
Source: PubMed

ABSTRACT The role of inhaled corticosteroids in the treatment of recurrent or persistent wheeze in infancy remains unclear. We evaluated the effect of 3 months of treatment with inhaled fluticasone propionate, 200 microg daily (FP200), on lung function and symptom scores in wheezy infants. Moreover, we evaluated whether infants with atopy and/or eczema respond better to FP200 as compared with non-atopic infants. Forced expiratory flow (Vmax(FRC)) was measured at baseline and after treatment. Sixty-five infants were randomized to receive FP200 or placebo, and 62 infants (mean age, 11.3 months) completed the study. Mean Vmax(FRC), expressed as a Z score, was significantly below normal at baseline and after treatment in both groups. The change from baseline of Vmax(FRC) was not different between the two treatment arms. After 6 weeks of treatment, and not after 13 weeks, the FP200 group had a significantly higher percentage of symptom-free days and a significant reduction in mean daily cough score compared with placebo. Separate analysis of treatment effect in infants with atopy or eczema showed no effect modification. We conclude that in wheezy infants, after 3 months of treatment with fluticasone, there was no improvement in lung function and no reduction in respiratory symptoms compared with placebo.


Available from: Anna A P H Vaessen-Verberne, Apr 18, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Uncomplicated upper respiratory viral infections are the most common cause of days lost from work and school and exert a major economic burden. In susceptible individuals, however, common respiratory viruses, particularly human rhinoviruses, also can have a major impact on diseases that involve the lower airways, including asthma, chronic obstructive pulmonary diseases (COPD) and cystic fibrosis (CF). Respiratory virus-induced wheezing illnesses in early life are a significant risk factor for the subsequent development of asthma, and virus infections may also play a role in the development and progression of airway remodeling in asthma. It is clear that upper respiratory tract virus infections can spread to the lower airway and trigger acute attacks of asthma, COPD or CF. These exacerbations can be life-threatening, and exert an enormous burden on health care systems. In recent years we have gained new insights into the mechanisms by which respiratory viruses may induce acute exacerbations of lower airway diseases, as well as into host defense pathways that may regulate the outcomes to viral infections. In the current article we review the role of viruses in lower airway diseases, including our current understanding on pathways by which they may cause remodeling and trigger acute exacerbations. We also review the efficacy of current and emerging therapies used to treat these lower airway diseases on the outcomes due to viral infection, and discuss alternative therapeutic approaches for the management of virus-induced airway inflammation. Copyright © 2014. Published by Elsevier Inc.
    Pharmacology [?] Therapeutics 12/2014; 148. DOI:10.1016/j.pharmthera.2014.12.005 · 7.75 Impact Factor
  • Source
    Allergologia et Immunopathologia 02/2008; 36(1):31-52. DOI:10.1157/13115669 · 1.58 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The usefulness of repeated lung function testing (LFTing) in asthmatic children should be to maintain lung function within the range of normal, and to prevent loss of lung function or reduced lung growth. Loss of lung function has been identified before 6 years of age, a period of time during which LFTing in not recommended because it is not routinely usable and may be unreliable. Moreover, until now, studies failed to demonstrate, in the long term, any clinical or functional benefit from early intervention in wheezy infants. After 6 years of age, any respiratory impairment would remain stable throughout childhood and until adulthood, whereas reduced lung growth is detected in children with current asthma whichever their treatment. In conclusions, repeated LFTings in asthmatic children allow the assessment but not the prevention of lung function impairment or loss.
    Revue Française d'Allergologie 04/2013; 53(3):159–163. DOI:10.1016/j.reval.2013.01.006 · 0.35 Impact Factor